Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Prices 5.5M Share Offering

NEW YORK (GenomeWeb News) – Rosetta Genomics has priced a public offering of 5.5 million shares of common stock at $5 per share, the firm said today.

The microRNA diagnostics developer said it expects gross proceeds from the offering to be around $27.5 million. It expects to close the financing on or around Aug. 8, and it has granted underwriters an option to purchase 825,000 shares to cover over-allotments.

Rosetta said it would use proceeds to fund operations and general corporate purposes, as well as to repay debt, provide working capital, defend its intellectual property, and support R&D efforts, among other uses.

Rosetta's shares were down 15 percent at $4.90 in Friday morning trade on the Nasdaq.

Its stock price has fallen sharply over the past two weeks, and was down 31 percent for the month of July. The recent decline follows a jump in the firm's shares in late May after it had effected a one-for-15 reverse split, enabling the firm to regain Nasdaq compliance.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.